Role of Inhibitory Check Point (CTLA-4) in Iraqi Women with Breast Cancer

Authors

  • Hamed Hussein Ali Al- Saadi
  • Hazima Mossa Al-Abassi
  • Mohammed Mahdi Jawad

DOI:

https://doi.org/10.37506/ijfmt.v15i3.15664

Keywords:

CTLA-4, Iraq, Breast cancer, Women

Abstract

Breast cancer is the most important and frequently diagnosed cancer among women worldwide. The CTLA4 is a member of Immunoglobulin super family and binds to the CD80 and CD86 co-stimulatory molecules.
(binds to CD80/86 on APCs with a higher affinity than CD28, thereby inhibiting co-stimulatory signals.
CTLA-4 (Gene ID:1493, MIM number: 123890) is a new member of the immunoglobulin super family
known as insulin-dependent diabetes mellitus 12 (IDDM 12) ,and cluster of differentiation 152 (CD152).
The CTLA-4 protein consists of a 37 amino acid leader peptide, an extracellular immunoglobulin (Ig) V like
domain or the ligand-binding domain (116 amino acid), a hydrophobic trans membrane region (37 amino
acid), and a cytoplasmic domain. The aim of the present study of the association of CTLA-4 serum level
and polymorphism with breast cancer in Iraqi women suffers from breast cancer. Materials and Methods:
peripheral Blood samples were collected from 45 Iraqi patients women diagnosed with breast cancer patient,
and 45 healthy women were matched with patients as a control. ELISA technique has been used to determine
the serum level of sCTLA-4.The polymerase chain reaction (PCR) performed on 45 patients and 45 control,
to determine the genetic variation in the +49 exon 1 region of CTLA-4 gene. Results: the serum level
of understudying groups recorded an non-significant difference increasing in the serum level of CTLA-4
under (p>0.05). in mean ± SE (3.17 ± 0.82 ng/ml) patients as compared to control (2.72 ± 0.29 ng/ml)
under (p>0.05). Genetic polymorphism of CTLA.4 gene (rs231775) which illustrated the distribution of
genotypes of CTLA.4 in patients and control. The heterozygous genotype AG recorded high frequency in
patients (35.56%) than control (0.00%) with a highly significant difference under (P<0.05). Homozygote
genotype AA recorded high frequency in control (95.56%) than patients (64.44) and has a highly significant
difference, and the homozygous genotype GG frequency (0.00%) was non- significant in patients compared
to control (4.44%). The allele frequency for allele A was (0.82%) in patients compared with control (0.96%)
while for the frequency of allele G was (0.18%) in patients compared with control (0.04%) with a significant
difference. Conclusion: elevation of serum concentration of sCTLA-4 could consider as a clinical biomarker
for prognosis breast cancer. There are some difference noticed in CTLA-4 gene with SNP (rs231775A/G)
which showed a significant differences between patients and control, A allele of SNP (rs231775A/G) may
have role to prevent the risk of breast cancer in Iraqi females, while allele G has an etiological fraction.

Author Biographies

Hamed Hussein Ali Al- Saadi

M.Sc. Student, Department of Biology / College of Education for Pure Science (Ibn Al-Haitham) / University of
Baghdad, Iraq

Hazima Mossa Al-Abassi

Assist. Prof., Department of Biology / College of Education for Pure Science (Ibn Al-Haitham) /
University of Baghdad, Iraq,

Mohammed Mahdi Jawad

Assist. Prof., Department of Biology / College of Education for Pure Science (Ibn AlHaitham) / University of Baghdad, Ira

Published

2021-05-17

How to Cite

Hamed Hussein Ali Al- Saadi, Hazima Mossa Al-Abassi, & Mohammed Mahdi Jawad. (2021). Role of Inhibitory Check Point (CTLA-4) in Iraqi Women with Breast Cancer. Indian Journal of Forensic Medicine & Toxicology, 15(3), 2337-2347. https://doi.org/10.37506/ijfmt.v15i3.15664